All In Biotech

BLA 761150 · Tersera Therapeutics LLC

Margenza

Margetuximab-Cmkb · Injection · HER2/neu Receptor Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Jan 15, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Dec 16, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

11

2 Phase 3, 1 recruiting

FAERS reports

27

14 serious, 9 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Left Ventricular Dysfunction: MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant decrease in left ventricular function. ( 2.2 , 5.1 , 6.1 ) Embryo-Fetal Toxicity: Exposure to MARGENZA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception. ( 5.2 , 8.1 , 8.3 ) Left Ventricular Dysfunction: MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant...

What it is approved for

From the label in effect Feb 11, 2025.

MARGENZA is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease [see Dosage and Administration (2.1) and Clinical Studies (14.1) ]. MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. ( 1 , 2.1 , 14.1 )

Mechanism: Margetuximab-cmkb binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC). In vitro, the modified Fc region of margetuximab-cmkb increases binding to activating Fc receptor FCGR3A (CD16A) and decreases binding to inhibitory Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and NK cell activation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MARGENZA · MARGETUXIMAB-CMKB 250MG/10ML(25MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Margetuximab" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death5
  • disease progression5
  • chills3
  • infusion related reaction2
  • abdominal pain1
  • alopecia1
  • anaphylactic reaction1
  • asthenia1
  • blood pressure decreased1
  • cardiac disorder1
  • constipation1
  • diarrhoea1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20218
202212
20234
20241
20251
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Margenza (Margetuximab-Cmkb) · HCPCS J9353

2024 spending

$5.3M

Beneficiaries

110

520 claims

Per beneficiary

$47,995

2024 ASP limit $47.61 per unit

View as table
YearSpending
2020$0
2021$2,339,272
2022$5,879,953
2023$5,363,231
2024$5,279,486

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Tersera Therapeutics LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.